Great work by @Yuz6Yusof ANA positive and diagnosis , prediction tool to rule out/ in autoimmune pathology. 1-High interferon score. 2-FH autoimmune disease. 3- More criteria. ?Monogenic error of immune system , ?genome assessment . @RheumNow , Daily recap

I vote for the ❤️ Several abstracts evaluated cardiovascular event prevalence and screening tools using ECHO, carotid ultrasound as current CV risk calculators are inadequate when assessing SLE CV risk. See my blog - just published @RheumNow https://t.co/XLc0YHtJ0B https://t.co/oF0fXBRM6O

Sunday recap @RheumNow Very interesting abstracts: https://t.co/BX8bDSX1M3 1- Fecal calprotectin in SpA population. 2-SLE; high or low steroids? Rapid or slow taper? 3-Molecular biomarkers for PAH in SLE. 4-Repeating imaging in ? Chronic back pain? And others …….

#ACR23 Abstr#0784 Beyond renal response, let’s also focus on kidney function and Steroid-sparing effect. Post-hoc analysis of Phase 2 RCT showed Obinutuzumab preserved eGFR by 4ml/min/1.73m2/year with greater number of pts achieving <7.5mg/d of prednisolone bs PBO @RheumNowNews https://t.co/2hW74UF1ta

#ACR23 Abstr#0590 Graphical Abstract makes it easy to follow 👏. Data using EHR showed that in #SLE with Diabetes, SGLT2-i vs DPP4-i was associated with reduced risks of developing AKI, CKD, ESRD, hospitalisation, and heart failure. Genital infection is common @RheumNowNews https://t.co/Iku6LqoYVb

#ACR23 Abstr#0571 As there is a genetic predisposition to #SLE, can polygenic risk score distinguish SLE vs ANA+ with no disease? A study in European ancestry showed modest discrimination (AUC: 0.66). This showed other contributors are vital in SLE development @RheumNowNews https://t.co/qiFOlOxq5r

#ACR23 Abstr#0785 So many debates re: HCQ dose 5mg/kg/d vs 6.5mg/kg/d - could blood monitoring help? A cohort study showed HCQ levels 750-1100 ng/mL was associated with reduced risk of #lupus activity by 76-90%. Need validation & assoc with retinal toxicity risk @RheumNowNews https://t.co/oRCHUG2dVA

#ACR23 Abstr#0548 Is there a risk prediction tool to help exclude non-immune pathology for Rheumatologists with newly referred ANA+? 3-yr data showed 3 BL markers: IFN score B, criteria No & FH of RMD had 98% specificity. Cd help inform early Tx trials in High Risk @RheumNowNews https://t.co/DCAg4EwM9d

Or to quote the great Murray Urowitz @UHN "a #lupus pregnancy has four trimesters"! #ACR23 https://t.co/Iw2S81tiTH

✅ Question to YOU attending #ACR23 ➡️ We're almost at the end of 2023 ⌛and many great #lupus data are being presented at @ACRheum Convergence 2023 in San Diego 👍 What would YOU update/change 🔄 regarding the management of #lupus in 2024 compared to 2023? 🧭 https://t.co/xpSXjuDjyr

ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno

Pregnant women with ARDs esp. SLE nephritis and primary APS have significantly higher risks for acute CVEs compared to those without these conditions. 25-30% of CVEs occurred during the postpartum period, Dhital R Abst#0722 #ACR23 #ACRBest @RheumNow https://t.co/m9FjsAu64N https://t.co/1dyTzgH97A

ACR 2023 Daily Recap - SUNDAY https://t.co/X9NNGLe78z

• Dr. John Cush

Urinary biomarkers precede loss of kidney fxn in LN by @andreafava #Ab0850 @RheumNow #ACR23 73 pts w LN. 44% devel GFR loss Elevation of urinary biomark of histo activity at 6, 12 mo predict GFR loss at 3 yrs - esp IL-16, >> proteinuria Combo biomark 12 mo: AUC 0.95 #ACRBest https://t.co/M7sfpCm7Kz